| The inventory of depressive symptomatology (IDS): Validity and reliability of clinician (IDS-C30) and self-report form (IDS-SR30) in patients with major depressive disorder | Selçuk ASLAN, Erdal IŞIK, Çepik Aslı KURUOĞLU, Sedat IŞIKLI, Augustus John RUSH, Ender TANER | 1–14 |
| Prevalence of cigarette, alcohol and substance use in children working or living on streets and the influencing factors | Resul BUĞDAYCI, Hanife TEZCAN, Tayyar ŞAŞMAZ, Ful UĞURHAN, Ahmet Öner KURT, Seva ÖNER | 15–21 |
| Psychiatric referral and treatment in children and adolescents with epilepsy | Kağan GÜRKAN, Ümran TÜZÜN | 22–30 |
| Neuroleptic malignant syndrome and neuropsychiatric sequelaes: A retrospective study | Hasan KANDEMİR, Neslihan CANSEL, Murat Eren ÖZEN, HAluk A. SAVAŞ, Mehmet YUMRU | 31–34 |
| Venlafaxine in the treatment of depression in schizophrenia | Esen Ayşen DANACI, Ömer AYDEMİR | 35–38 |
| Galactorrhea during escitalopram treatment: A case report | Alper EVRENSEL, Murat GÜLSÜN, Samet VERİM | 39–41 |
| Severe extrapyramidal symptoms due to valproate plus low dose olanzapine: A case report | İhsan Tuncer OKAY, Demet DANKI, Nesrin DİLBAZ | 42–46 |
| Very early onset schizophrenia and clozapine: Case report | Özlem DOĞAN, Pekcanlar Aykut AKAY, İnal F. Neslihan EMİROĞLU | 47–51 |
| Importance of depressive symptoms in schizophrenia and theirs pharmacotherapies | Bülent KAYAHAN, Baybars VEZNEDAROĞLU | 52–62 |
| What is chronic fatigue immune dysfunction syndrome? | Akif ASDEMİR, Seher SOFUOĞLU, Hasan Basri İZGİ | 63–76 |